WallStSmart

Claritev Corporation (CTEV)vsR1 RCM Inc (RCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

R1 RCM Inc generates 152% more annual revenue ($2.46B vs $978.76M). RCM leads profitability with a -2.5% profit margin vs -29.3%. RCM earns a higher WallStSmart Score of 39/100 (F).

CTEV

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 5.0Quality: 5.5
Piotroski: 4/9Altman Z: -0.49

RCM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.7Quality: 6.0
Piotroski: 6/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CTEV.

RCMUndervalued (+27.7%)

Margin of Safety

+27.7%

Fair Value

$19.79

Current Price

$14.31

$5.48 discount

UndervaluedFair: $19.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTEV1 strengths · Avg: 10.0/10
Debt/EquityHealth
-19.1110/10

Conservative balance sheet, low leverage

RCM1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

CTEV4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$447.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-646.0%2/10

ROE of -646.0% — below average capital efficiency

Free Cash FlowQuality
$-95.41M2/10

Negative free cash flow — burning cash

RCM4 concerns · Avg: 2.8/10
PEG RatioValuation
2.064/10

Expensive relative to growth rate

Operating MarginProfitability
3.8%3/10

Operating margin of 3.8%

Return on EquityProfitability
-2.2%2/10

ROE of -2.2% — below average capital efficiency

EPS GrowthGrowth
-99.3%2/10

Earnings declined 99.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTEV

The strongest argument for CTEV centers on Debt/Equity.

Bull Case : RCM

The strongest argument for RCM centers on Price/Book. Revenue growth of 14.7% demonstrates continued momentum.

Bear Case : CTEV

The primary concerns for CTEV are EPS Growth, Market Cap, Return on Equity.

Bear Case : RCM

The primary concerns for RCM are PEG Ratio, Operating Margin, Return on Equity.

Key Dynamics to Monitor

RCM carries more volatility with a beta of 0.84 — expect wider price swings.

RCM is growing revenue faster at 14.7% — sustainability is the question.

RCM generates stronger free cash flow (60M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RCM scores higher overall (39/100 vs 34/100) and 14.7% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Claritev Corporation

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Claritev Corporation, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company is headquartered in New York, New York.

Visit Website →

R1 RCM Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

R1 RCM Inc (RCM) is a leading provider of technology-driven revenue cycle management solutions that significantly enhance the financial performance of healthcare organizations across the United States. By leveraging advanced analytics and deep industry expertise, R1 RCM offers comprehensive services that optimize billing processes and improve operational efficiency for hospitals and outpatient facilities alike. The company’s innovative approach not only enhances revenue capture but also elevates patient experiences, establishing R1 RCM as a critical player in the evolving healthcare sector. With a strong emphasis on expanding its service offerings and increasing market share, R1 RCM is strategically positioned to capitalize on the growing demand for sophisticated revenue cycle management services.

Want to dig deeper into these stocks?